drugset / Trial / NCT02860052

SB208 for the Treatment of Tinea Pedis

NCT02860052 ↗

Phase 2 Completed 222 enrolled Novan, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in non immunocompromised adult subjects with interdigital tinea pedis.

Timeline

Start
2016-07-19
Primary completion
2017-01
Completion
2017-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject BERDAZIMER SODIUM Small molecule 2 % Topical
Subject BERDAZIMER SODIUM Small molecule 4 % Topical
Subject BERDAZIMER SODIUM Small molecule 16 % Topical

Indications